期刊论文详细信息
BMC Cancer
MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy
Wentao Liu2  Lin Qi4  Hui Lv1  Xiongbing Zu4  Minfeng Chen4  Jun Wang3  Longfei Liu4  Feng Zeng4  Yuan Li4 
[1] Department of Pathology, Xiangya School of Medicine, Central South University, Changsha City, Hunan Province, P. R. China
[2] Present address: Department of Urology, The second Xiangya Hospital, Central South University, Changsha City, Hunan Province, P. R. China
[3] Department of Urology, First Teaching Hospital, Zhengzhou University, Zhengzhou City, Henan Province, P. R. China
[4] Department of Urology, Xiangya Hospital, Central South University, No.87 Xiangya Road, Changsha City 410008, Hunan Province, P. R. China
关键词: Lymph node dissection;    Bladder cancer;    EMT;    Invasive;    microRNA;   
Others  :  1136251
DOI  :  10.1186/s12885-015-1110-7
 received in 2014-10-02, accepted in 2015-02-20,  发布年份 2015
PDF
【 摘 要 】

Background

MicroRNAs (miRNAs) are small non-coding RNAs that silence their cognate target genes by specifically binding and cleaving messenger RNAs or inhibiting their translation. In this study, we explored whether miRNA-141 and miRNA-200b are involved in regulation of the invasive ability and epithelial–mesenchymal transition (EMT) of bladder cancer cells in vitro. We also evaluated their potential as biomarkers for deciding the extent of pelvic lymph node dissection (PLND) required during radical cystectomy.

Methods

Pri- and anti-miR cell lines were constructed. The invasive capacity of the cells was tested using a cell invasion assay. The MMP-2, MMP-9 and EMT-related markers were validated through Western blotting analysis. Seventy-eight urine samples from patients undergoing cystectomy and super-extended lymph node dissection were evaluated by qRT-PCR.

Results

Loss of expression of miRNA-141 and miRNA-200b was associated with increased invasion and migration ability, upregulated MMP-2, MMP-9, vimentin and N-cadherin expression, and downregulated E-cadherin expression in bladder cancer cell lines. Urine miRNA-141 and miRNA-200b levels could discriminate patients with lymph node metastasis from those who were lymph node negative (AUC: 0.704 and 0.674, respectively).

Conclusion

MiRNA-141 and miRNA-200b play important roles in the invasive ability and EMT phenotype of bladder cancer. Detection of miRNA-141 and miRNA-200b can help to identify patients undergoing cystectomy who are likely to have lymph node metastasis, and therefore those who may benefit from super-extended PLND.

【 授权许可】

   
2015 Liu et al.; licensee BioMed Central.

【 预 览 】
附件列表
Files Size Format View
20150312013838855.pdf 1873KB PDF download
Figure 4. 24KB Image download
Figure 3. 55KB Image download
Figure 2. 118KB Image download
Figure 1. 92KB Image download
【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】
  • [1]Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA: Cancer J Clin 2013, 63(1):11-30.
  • [2]Wang S, Xue S, Dai Y, Yang J, Chen Z, Fang X, et al.: Reduced expression of microRNA-100 confers unfavorable prognosis in patients with bladder cancer. Diagn Pathol 2012, 7:159. BioMed Central Full Text
  • [3]von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al.: Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005, 23(21):4602-8.
  • [4]Witjes JA, Comperat E, Cowan NC, De Santis M, Gakis G, Lebret T, et al.: EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur Urol 2014, 65(4):778-92.
  • [5]Stein JP, Quek ML, Skinner DG: Lymphadenectomy for invasive bladder cancer: I. historical perspective and contemporary rationale. BJU Int 2006, 97(2):227-31.
  • [6]Abol-Enein H, El-Baz M, Abd El-Hameed MA, Abdel-Latif M, Ghoneim MA: Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study—a single center experience. J Urol 2004, 172(5):1818-21.
  • [7]Stein JP, Skinner DG: Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006, 24(3):296-304.
  • [8]Leissner J, Ghoneim M, Abol-Enein H, Thüroff J, Franzaring L, Fisch M, et al.: Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study. J Urol 2004, 171(1):139-44.
  • [9]Shao P, Meng X, Li J, Lv Q, Zhang W, Xu Z, et al.: Laparoscopic extended pelvic lymph node dissection during radical cystectomy: technique and clinical outcomes. BJU Int 2011, 108(1):124-8.
  • [10]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116(2):281-97.
  • [11]Catto JW, Alcaraz A, Bjartell AS, De Vere WR, Evans CP, Fussel S, et al.: MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 2011, 59(5):671-81.
  • [12]Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, et al.: An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer 2012, 107(1):123-8.
  • [13]Korpal M, Lee ES, Hu G, Kang Y: The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008, 283(22):14910-4.
  • [14]Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al.: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10(5):593-601.
  • [15]Wiklund ED, Bramsen JB, Hulf T, Dyrskjøt L, Ramanathan R, Hansen TB, et al.: Coordinated epigenetic repression of the miR-200 family and miR-205 in invasive bladder cancer. Int J Cancer 2011, 128(6):1327-34.
  • [16]Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, et al.: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 2007, 25(5):387-92.
  • [17]Dyrskjøt L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al.: Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res 2009, 69(11):4851-60.
  • [18]Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods 2001, 25(4):402-8.
  • [19]Yuan JB, Zu XB, Miao JG, Wang J, Chen MF, Qi L: Laparoscopic pelvic lymph node dissection system based on preoperative primary tumour stage (T stage) by computed tomography in urothelial bladder cancer: results of a single-institution prospective study. BJU Int 2013, 112(2):E87-91.
  • [20]Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al.: The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55(4):815-25.
  • [21]Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J-C, et al.: pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011, 12(1):77. BioMed Central Full Text
  • [22]Liu L, Zhao X, Zhu X, Zhong Z, Xu R, Wang Z, et al.: Decreased expression of miR-430 promotes the development of bladder cancer via the upregulation of CXCR7. Mol Med Rep 2013, 8(1):140-6.
  • [23]Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S, et al.: Jin S: miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett 2013, 339(2):260-9.
  • [24]Liu J, Mil A, Aguor EN, Siddiqi S, Vrijsen K, Jaksani S, et al.: MiR-155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPCs) via targeting of MMP-16. J Cell Mol Med 2012, 16(10):2379-86.
  • [25]Pacurari M, Addison JB, Bondalapati N, Wan Y-W, Luo D, Qian Y, et al.: The microRNA-200 family targets multiple non-small cell lung cancer prognostic markers in H1299 cells and BEAS-2B cells. Int J Oncol 2013, 43(2):548-60.
  • [26]Kenney PA, Wszolek MF, Rieger Christ KM, Neto BS, Gould JJ, Harty NJ, et al.: Novel ZEB1 expression in bladder tumorigenesis. BJU Int 2011, 107(4):656-63.
  • [27]Abol-Enein H, Tilki D, Mosbah A, El-Baz M, Shokeir A, Nabeeh A, et al.: Does the extent of lymphadenectomy in radical cystectomy for bladder cancer influence disease-free survival? A prospective single-center study. Eur Urol 2011, 60(3):572-7.
  • [28]Shariat SF, Ehdaie B, Rink M, Cha EK, Svatek RS, Chromecki TF, et al.: Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol 2012, 61(2):237-42.
  • [29]Lin H, Castillo L, Mahon K, Chiam K, Lee B, Nguyen Q, et al.: Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer. Br J Cancer 2014, 110(10):2462-71.
  • [30]Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al.: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014, 259(4):735-43.
  • [31]Jang K, Ahn H, Sim J, Han H, Abdul R, Paik SS, et al.: Loss of microRNA-200a expression correlates with tumor progression in breast cancer. Transl Res 2014, 163(3):242-51.
  • [32]Men D, Liang Y, Chen L: Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol 2014, 38(2):152-6.
  • [33]Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, Iglesias-Díaz P, Lorenzo-Patiño MJ, Haz M, et al.: Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med 2012, 10(1):186. BioMed Central Full Text
  文献评价指标  
  下载次数:107次 浏览次数:26次